Premium
Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study group
Author(s) -
Kristiansen K.,
Hagen S.,
Kollevold T.,
Torvik A.,
Holme I.,
Stat M,
Nesbakken R.,
Hatlevoll R.,
Lindgren M.,
Brun A.,
Lindgren S.,
Notter G.,
Andersen A. P.,
Elgen K.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810215)47:4<649::aid-cncr2820470405>3.0.co;2-w
Subject(s) - medicine , bleomycin , radiation therapy , placebo , astrocytoma , prospective cohort study , multicenter trial , surgery , chemotherapy , randomized controlled trial , multicenter study , glioma , pathology , alternative medicine , cancer research
In a controlled, prospective, randomized investigation, started in 1974, 118 patients with supratentorial astrocytoma Grade III–IV were divided into three groups. Groups 1 and 2 received 45 Gy postoperatively to the whole supratentorial brain. Bleomycin in 15‐mg doses and a total dose of 180 mg or placebo was given intravenously three times a week, one hour prior to radiotherapy, during weeks 1,2,4 and 5. Group 3 received conventional care but no radiotherapy or chemotherapy. Median survival rates of patients were 10.8 months in Groups 1 and 2, and 5.2 months in Group 3, a statistically significant difference. With regard to performance, the patients in Group 3 deteriorated faster than patients in Groups 1 and 2. Bleomycin had no positive or negative influence on survival.